Characteristics | Â | IgAN n = 40 | IgMN n = 37 | MesPGN without IgA/IgM n = 21 | P |
---|---|---|---|---|---|
Age, years |  | 10.2 [3.9‒15] | 9.4 [3.9‒13.6] | 6.2 [2.8‒13.2] | .002 |
Sex, male/ female | Â | 28/12 | 20/17 | 10/11 | NS |
Body weight, kg |  | 33.5 [15.5‒71] | 27 [14‒62.5] | 20 [14‒65] | .015 |
Duration of disease prior to biopsy, months |  | 2 [0.23‒120] | 12 [0.33‒84] | 6 [0.67‒48] | .012 |
Hematuria, n (%) | Â | 39 (98) | 36 (97) | 21 (100) | NS |
Macro hematuria, n (%) | Â | 25 (63) | 7 (19) | 4 (19) | .000 |
Proteinuria > 4mg/m2/h, n (%) | Â | 27 (68) | 18 (49) | 11 (52) | NS |
Proteinuria > 40mg/m2/h, n (%) | Â | 16 (40) | 8 (22) | 4 (19) | NS |
Serum creatinine > 1.5mg/dl, n (%) | Â | 1 (3) | 0 (0) | 0 (0) | NS |
Hypertensiona, n (%) | Â | 4 (10) | 2 (5) | 2 (10) | NS |
Clinical features, n (%) | Isolated hematuria | 13 (33) | 19 (51) | 10(48) | NS |
 | Proteinuria with or without hematuria | 18 (45) | 10 (27) | 6 (29) | NS |
 | Nephritic syndromeb | 2 (5) | 1 (3) | 0 (0) | NS |
 | Nephrotic syndromec | 6 (15) | 7 (19) | 5 (24) | NS |
 | Acute kidney injuryd | 1 (3) | 0 (0) | 0 (0) | NS |
Histological features, n (%) | Adhesion | 12 (30) | 8 (22) | 8 (38) | NS |
Sclerosis | 5 (13) | 0 (0) | 1 (5) | NS | |
Crescent | 1 (3) | 0 (0) | 0 (0) | NS | |
Endocapillary hypercellularity | 8 (20) | 2 (5) | 3 (14) | NS | |
Tubular atrophy | 9 (23) | 5 (14) | 4 (19) | NS | |
Interstitial fibrosis | 2 (5) | 2 (5) | 1 (5) | NS | |
Interstitial inflammation | 6 (15) | 4 (11) | 2 (10) | NS | |
Arteriolar lesions | 0 (0) | 0 (0) | 0 (0) | NS | |
Severe MC (score ≥ 2)e | 20 (50) | 9 (24) | 5 (24) | .030 | |
Severe GS (score ≥ 2)f | 9 (23) | 5 (14) | 3 (14) | NS | |
Severe TID (score ≥ 2)g | 11 (28) | 5 (14) | 4 (19) | NS | |
Severe MC + severe GS | 6 (15) | 2 (5) | 2 (10) | NS | |
Severe MC + severe TID | 6 (15) | 2 (5) | 2 (10) | NS | |
Severe GS + severe TID | 5 (13) | 3 (8) | 0 (0) | NS | |
Severe MC + GS + TID | 3 (8) | 1 (3) | 0 (0) | NS | |
Treatmen, n (%) | Prednisone | 18 (45) | 14 (38) | 7 (33) | NS |
 | Cyclophosphamide | 4 (10) | 3 (8) | 3 (14) | NS |